Unlocking the Antiadipogenic Potential of Carotenoids From Galdieria phlegrea
Giustino E., Imbimbo P., Trepiana J., Portillo MP., Monti DM.
Animal Study, published in Biofactors (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Biofactors (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 40470712
- PMCID
- PMC12138963
- DOI
- 10.1002/biof.70027
Abstract (original English)
Oxidative stress, a sedentary and inactive lifestyle, or a high-fat diet are among the main causes responsible for the alteration of skin topography, a complex multifactorial disorder of the deeper layers of the skin, mainly caused by an impairment of lipid production, degradation, and storage. Natural bioactive compounds can improve skin health and appearance as well as reassure consumers' about the safety of the molecules used in cosmetics. Carotenoids from microalgae are receiving attention because of their potent antioxidant activity. Here, a carotenoid extract from Galdieria phlegrea residual biomass was successfully explored for its ability to inhibit in vitro skin hyperpigmentation, to interfere with 3T3-L1 adipocytes differentiation, as well as to affect de novo lipogenesis and enhance lipolysis in mature adipocytes. The same set of experiments was done in parallel on the extract obtained from fresh biomass, but no biological activity was observed. The obtainment of a high-value class of molecules in a cascade approach highlights the importance of a biorefinery approach to obtain active extracts with a concurrent lowering of the overall process costs.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.